Anne Kerber
Management
Affimed
Germany
Biography
Anne Kerber joined Affimed in January 2016 as Senior Medical Director and Head of Operations. She was appointed Vice President Medical in August 2016, also leading the Company’s clinical development team as interim CMO. Dr. Kerber joined Affimed from Merck KGaA, where she held multiple positions in clinical development, most recently as Global Clinical Lead for EGFR-targeting therapies. At Merck, she was responsible for developing both early and late stage clinical development strategies for novel chemical and biological entities in various cancer indications including glioblastoma, lung, head and neck, colorectal, and prostate cancers, as well as other solid tumors. Dr. Kerber acted as medical representative in global product teams and has a strong track record in designing and conducting Phase 1-3 clinical studies in Europe, the US, China and Japan. During her academic career, she was an investigator in numerous clinical studies in oncology including gastrointestinal, breast, ovarian, and lung cancer, as well as lymphomas. Dr. Kerber holds an M.D. from the University of Marburg, Germany and became a board certified Internist and Hematologist/Oncologist at the University Hospital and at Nordwest Hospital, respectively, both in Frankfurt/Main, Germany. Additionally, she holds a degree in Pharmaceutical Medicine, from the University Basel, Switzerland.
Research Interest
Oncology
